S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.54
+1.86
+11.15%
TNXP · Tonix Pharmaceuticals Holding Corp.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Tonix Pharmaceuticals Holding Corp (TNXP)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$5.45
-0.31
(-5.46%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$5.45
$5.39
$5.99
52-WEEK RANGE
$5.45
$5.54
$20.58
What's happening
- TNXP is down 5.46% today, trading at $5.45. — Live quote
- It's trading within 3% of its 52-week low ($5.54). (Finnhub fundamentals)
- Volume today (38,340) is well below its 3-month average of 602,060. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-2.44 actual vs. $-2.75 estimated (+11.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TNXP
-63.00%
vs S&P 500
-75.77%
1-YEAR RETURN
TNXP
-70.87%
vs S&P 500
-85.43%
6-MONTH RETURN
TNXP
-59.09%
3-MONTH RETURN
TNXP
-50.00%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-2.44
Est. $-2.75
BEAT +11.3%
2026-04-26 (Q1 2026)
$-2.93
Est. $-2.48
MISS -18.1%
2026-01-26 (Q4 2025)
$-3.98
Est. $-3.25
MISS -22.3%
2025-10-26 (Q3 2025)
$-3.59
Est. $-3.66
BEAT +1.8%
Valuation Measures & Ratios
Enterprise Value4-$77.1M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)3.41
Price / Book70.92
EV4 / Revenue-2.65
EV4 / EBITDA—
Profit Margin-548.64%
Operating Margin-568.43%
Return on Equity (ROE8)-68.99%
Return on Assets (ROA9)-61.32%
Avg Volume (3M)602,060
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $211.9M | $188.8M | $215.1M | $262.8M | $106.0M |
| P/E | -1.50 | -1.61 | -2.35 | -1.90 | -0.85 |
| Price/Sales | 8.24 | 12.93 | 20.41 | 27.79 | 10.66 |
| Price/Book | 0.95 | 0.83 | 0.93 | 1.56 | 0.59 |
| EV/Revenue | 1.39 | 0.23 | 2.37 | 14.54 | -2.59 |
| EV/EBITDA | -0.25 | -0.03 | -0.27 | — | — |
| ROE | -63.45% | -51.65% | -39.51% | -82.20% | -69.16% |
| ROA | -55.50% | -45.48% | -36.18% | -73.70% | -64.68% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,937,499
Change from Prior Settlement+3.49%
% of Float—
Days to Cover (Short Ratio)5.90
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 577.9% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -548.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -70.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TNXP
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5M | $6.9M | $3.3M | $2.0M | $2.4M | $2.8M | $2.2M | $2.5M |
| Operating income | -$42.5M | -$41.5M | -$33.1M | -$28.3M | -$16.1M | -$15.6M | -$77.3M | -$21.4M |
| Net income | -$40.6M | -$40.2M | -$32.0M | -$28.3M | -$16.8M | -$14.2M | -$78.8M | -$14.9M |
| EPS (diluted) | $-2.44 | $-2.93 | $-3.59 | $-3.86 | $-2.84 | $-22.68 | $-1920.85 | $-535.72 |
| EPS (basic) | $-2.44 | $-2.93 | $-3.59 | $-3.86 | $-2.84 | $-22.68 | $-1920.85 | $-535.72 |
| Operating margin | -$314 | -$604 | -$1.0K | -$1.4K | -$661 | -$551 | -$3.5K | -$860 |
| Net margin | -$299 | -$584 | -$973 | -$1.4K | -$693 | -$504 | -$3.6K | -$602 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $254.1M | $257.9M | $277.2M | $252.4M | $187.4M | $192.9M | $162.9M | $95.0M |
| Total liabilities | $31.8M | $30.8M | $32.0M | $21.3M | $19.4M | $12.5M | $23.3M | $20.8M |
| Stockholders' equity | $222.3M | $227.1M | $245.2M | $231.1M | $168.0M | $180.4M | $139.6M | $74.2M |
| Total current assets | $203.4M | $207.2M | $228.9M | $208.1M | $143.5M | $149.6M | $119.0M | $50.5M |
| Total current liabilities | $30.8M | $29.6M | $30.8M | $21.0M | $19.1M | $12.1M | $18.3M | $15.2M |
| Cash & equivalents | $176.2M | $185.5M | $207.6M | $190.1M | $125.3M | $131.7M | $98.8M | $28.2M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $11.8M | $8.8M | $6.3M | $3.5M | $2.3M | $3.3M | $3.7M | $4.0M |
| Inventory | — | — | — | — | — | — | $8.4M | $7.9M |
| Other current assets | — | — | — | — | — | — | — | $2.1M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $44.8M | $44.9M | $44.5M | $42.6M | $42.3M | $41.8M | $42.3M | $42.7M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | $120.0K | — | $120.0K | — | — | — | — | — |
| Other non-current assets | $4.5M | $4.3M | $2.3M | $1.3M | $931.0K | $910.0K | $951.0K | $951.0K |
| Accounts payable | $9.1M | $9.6M | $8.1M | $8.5M | $7.8M | $4.2M | $4.5M | $3.9M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | $3.8M | $4.2M | $3.4M | $2.7M | $3.0M | $1.9M | $1.8M | — |
| Short-term debt | — | — | — | — | — | — | $2.8M | $2.8M |
| Long-term debt | — | — | — | — | — | — | $4.7M | $5.2M |
| Common stock & paid-in capital | $17.0K | $14.0K | $13.0K | $10.0K | $8.0K | $7.0K | $4.0K | $156.0K |
| Retained earnings | -$935.5M | -$894.9M | -$854.7M | -$807.8M | -$775.8M | -$747.5M | -$730.7M | -$708.6M |
| Accumulated other comprehensive income (loss) | -$348.0K | -$283.0K | -$289.0K | -$274.0K | -$270.0K | -$266.0K | -$255.0K | -$250.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$42.2M | -$42.3M | -$39.6M | -$28.8M | -$14.8M | -$16.6M | -$14.6M | -$18.8M |
| Investing cash flow | -$587.0K | -$1.7M | -$1.0M | -$962.0K | -$2.5M | -$6.0K | -$3.0K | -$9.0K |
| Financing cash flow | $33.5M | $20.2M | $59.1M | $94.9M | $11.0M | $49.5M | $85.2M | $42.9M |
| Free cash flow | -$42.8M | -$44.0M | -$41.5M | -$29.7M | -$15.4M | -$16.6M | -$14.6M | -$18.8M |
| Capital expenditures | $587.0K | $1.7M | $1.9M | $962.0K | $527.0K | $6.0K | $3.0K | $9.0K |
| Depreciation & amortization | $619.0K | $555.0K | $488.0K | $461.0K | $483.0K | $493.0K | $496.0K | $510.0K |
| Share-based compensation | $2.3M | $2.0M | $1.8M | $1.9M | $1.4M | $882.0K | $894.0K | $1.0M |
| Change in accounts receivable | $3.0M | $2.5M | $2.8M | $1.2M | -$992.0K | -$371.0K | -$1.3M | $1.6M |
| Change in inventory | $2.9M | -$2.4M | -$364.0K | -$1.2M | $130.0K | -$272.0K | -$50.0K | -$1.2M |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | $7.8M | $2.9M | $2.9M | $3.0M | — | — |
| Debt repaid | — | — | $0 | $0 | $0 | $9.7M | $705.0K | $705.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.8M | — | — |
| Operating income | -$125.7M | -$136.7M | -$118.4M | -$112.1M | -$92.3M |
| Net income | -$124.0M | -$130.0M | -$116.7M | -$110.2M | -$92.3M |
| EPS (diluted) | $-14.57 | $-176.60 | $-14720.25 | $-20.01 | $-8.10 |
| EPS (basic) | $-14.57 | $-176.60 | $-14720.25 | $-20.01 | $-8.10 |
| Operating margin | -$959 | -$1.4K | -$1.5K | — | — |
| Net margin | -$946 | -$1.3K | -$1.5K | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $277.2M | $162.9M | $154.5M | $225.7M | $240.9M |
| Total liabilities | $32.0M | $23.3M | $48.9M | $18.5M | $22.2M |
| Stockholders' equity | $245.2M | $139.6M | $105.5M | $207.2M | $218.7M |
| Total current assets | $228.9M | $119.0M | $47.8M | $130.8M | $189.0M |
| Total current liabilities | $30.8M | $18.3M | $18.9M | $18.2M | $21.7M |
| Cash & equivalents | $207.6M | $98.8M | $24.9M | $120.2M | $178.7M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | $6.3M | $3.7M | — | — | — |
| Inventory | — | $8.4M | $13.6M | — | — |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $44.5M | $42.3M | $94.0M | $93.8M | $50.6M |
| Goodwill | — | — | $965.0K | — | — |
| Intangible assets | — | — | $9.6M | — | — |
| Other non-current assets | $2.2M | $951.0K | $1.1M | $264.0K | $379.0K |
| Accounts payable | $8.1M | $4.5M | $3.8M | $8.1M | $13.3M |
| Accrued liabilities | — | — | — | — | — |
| Deferred revenue (current) | $3.4M | $1.8M | $3.0M | $3.3M | — |
| Short-term debt | — | $2.8M | $2.4M | — | — |
| Long-term debt | — | $4.7M | $6.6M | — | — |
| Common stock & paid-in capital | $13.0K | $4.0K | $59.0K | $12.0K | $16.0K |
| Retained earnings | -$854.7M | -$730.7M | -$600.7M | -$470.0M | -$359.8M |
| Accumulated other comprehensive income (loss) | -$289.0K | -$255.0K | -$232.0K | -$167.0K | -$92.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$99.8M | -$60.9M | -$102.0M | -$98.1M | -$75.6M |
| Investing cash flow | -$4.5M | -$120.0K | -$29.1M | -$48.1M | -$35.3M |
| Financing cash flow | $214.5M | $134.9M | $36.5M | $87.8M | $212.5M |
| Free cash flow | -$103.2M | -$61.0M | -$109.9M | -$146.2M | -$110.9M |
| Capital expenditures | $3.4M | $120.0K | $7.9M | $48.1M | $35.3M |
| Depreciation & amortization | $1.9M | $3.4M | $4.3M | $1.3M | $50.0K |
| Share-based compensation | $6.0M | $4.8M | $9.3M | $10.9M | $7.9M |
| Change in accounts receivable | $2.6M | $3.7M | — | — | — |
| Change in inventory | -$1.7M | -$3.7M | -$61.0K | — | — |
| Purchases of investments | — | — | — | — | — |
| Share repurchases | $13.8M | — | $14.0M | — | — |
| Debt repaid | $9.7M | $2.4M | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TNXP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-05-15 to 2026-08-27
Recent transactions
- Insiders have net bought 14,415 shares over the last 182 days, across 5 purchases and 0 sales.
- Most recent: LEDERMAN SETH (Chief Executive Officer) — Open market purchase of 2,000 shares on 2026-08-27.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)14,415 sh(5 txns)
Sales (open market)0 sh(0 txns)
Net Shares+14,415
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| LEDERMAN SETH | Chief Executive Officer | Open market purchase | 2026-08-27 | 2,000 |
| BAGGER RICHARD H | Director | Open market purchase | 2026-08-20 | 1,000 |
| SAENGER BRADLEY | Chief Financial Officer | Other acquisition/disposition | 2026-06-30 | 1,453 |
| Taylor Carolyn E. | Director | Open market purchase | 2026-06-12 | 1,415 |
| Stillwell Richard Newcomb | Director | Open market purchase | 2026-06-08 | 5,000 |
| Treco James | Director | Open market purchase | 2025-08-20 | 250 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-27 | LEDERMAN SETH | Chief Executive Officer | Open market purchase | 2,000 | $13.79 |
| 2026-08-20 | BAGGER RICHARD H | Director | Open market purchase | 1,000 | $12.60 |
| 2026-06-30 | SAENGER BRADLEY | Chief Financial Officer | Other acquisition/disposition | 1,453 | $10.91 |
| 2026-06-12 | Taylor Carolyn E. | Director | Open market purchase | 1,415 | $10.55 |
| 2026-06-09 | LEDERMAN SETH | Chief Executive Officer | Open market purchase | 5,000 | $11.79 |
| 2026-06-08 | Stillwell Richard Newcomb | Director | Open market purchase | 5,000 | $11.65 |
| 2026-03-31 | LEDERMAN SETH | Chief Executive Officer | Open market purchase | 5,000 | $12.62 |
| 2026-03-18 | LEDERMAN SETH | Chief Executive Officer | Open market purchase | 15,000 | $14.89 |
| 2025-08-21 | Taylor Carolyn E. | Director | Open market purchase | 418 | $36.03 |
| 2025-08-20 | Treco James | Director | Open market purchase | 250 | $36.00 |
| 2025-05-15 | LEDERMAN SETH | Chief Executive Officer | Open market purchase | 4,000 | $21.55 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:15 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-02 | 8-K | 2026-10-01 | View on SEC.gov → |
| 2026-09-22 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-08-31 | 4 | 2026-08-27 | View on SEC.gov → |
| 2026-08-24 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-18 | 8-K | 2026-08-18 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-07-21 | 8-K | 2026-07-20 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-13 | View on SEC.gov → |
Recent news
Headlines about TNXP (Tonix Pharmaceuticals Holding Corp.). Links open the publisher — we don’t host full articles.
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 2026-10-21 -
Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
Yahoo · 2026-10-19 -
Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30
Benzinga · 2026-10-19 -
The Technical Signals Behind (TNXP) That Institutions Follow
Stock Traders Daily · 2026-10-17 -
TNXP 8-K & SEC Filings
Yahoo Finance · 2026-10-16 -
Live Tonix Pharmaceuticals Holding Corp. (TNXP) Technical Analysis
Traders Union · 2026-10-15 -
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
Yahoo · 2026-10-15
No headlines in this category right now — try “All”.